BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy

Completed

Conditions: Hepatitis C

First Posted Date: 2017-03-06

Last Posted Date: 2022-02-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 344

Registration Number: NCT03071133

Locations: 🇯🇵
Local Institution, Tokyo, Japan

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

Phase 3

Completed

Conditions: Melanoma

Interventions: Biological: nivolumab
Biological: ipilimumab

First Posted Date: 2017-03-01

Last Posted Date: 2021-09-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1844

Registration Number: NCT03068455

Locations: 🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇮🇹
Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy
🇮🇹
Istituto Oncologico Veneto IOV, Padova, Italy

and more 67 locations

Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BMS-931699

First Posted Date: 2017-02-23

Last Posted Date: 2017-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5

Registration Number: NCT03058822

Locations: 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

Phase 3

Withdrawn

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2017-02-09

Last Posted Date: 2018-04-17

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03048136

Locations: 🇵🇪
Local Institution, Lima, Peru

Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin

Phase 1

Completed

Conditions: Inflammatory Diseases
Autoimmune Diseases

Interventions: Drug: BMS-986165
Drug: Rosuvastatin

First Posted Date: 2017-02-07

Last Posted Date: 2017-04-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT03044873

Locations: 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States

Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Completed

Conditions: Chronic Phase Chronic Myeloid Leukemia

First Posted Date: 2017-02-07

Last Posted Date: 2022-12-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 118

Registration Number: NCT03045120

Locations: 🇺🇸
Mount Sinai Hospital, Chicago, Illinois, United States
🇺🇸
Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States
🇺🇸
The Cancer Institute At Alexian Brothers, Elk Grove Village, Illinois, United States

and more 20 locations

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

Phase 1

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: BMS-986166
Other: Placebo matching BMS-986166

First Posted Date: 2017-02-01

Last Posted Date: 2019-01-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 213

Registration Number: NCT03038711

Locations: 🇺🇸
PPD Development, LLC, Austin, Texas, United States

Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: BMS-986141 Form B tablet (low dose)
Drug: BMS-986141 Form A Tablet
Drug: BMS-986141 Form B tablet (high dose)

First Posted Date: 2017-01-30

Last Posted Date: 2018-03-23

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03035734

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

Phase 3

Active, not recruiting

Conditions: Urothelial Cancer

Interventions: Drug: Gemcitabine
Biological: Nivolumab
Biological: Ipilimumab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2017-01-30

Last Posted Date: 2024-10-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1322

Registration Number: NCT03036098

Locations: 🇺🇸
Local Institution - 0001, Anchorage, Alaska, United States
🇺🇸
Local Institution - 0115, Fresno, California, United States
🇺🇸
St Joseph Heritage Healthcare, Santa Rosa, California, United States

and more 171 locations

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma

Interventions: Biological: Opdivo
Biological: Yervoy

First Posted Date: 2017-01-24

Last Posted Date: 2022-06-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 104

Registration Number: NCT03029780

Locations: 🇨🇱
Centro Internacional de Estudios Clinicos, Recoleta, Santiago De Chile, Chile
🇨🇱
Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile
🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy